Search results for "EAD"

showing 10 items of 5911 documents

A large-scale screening for the taiga tick, Ixodes persulcatus, and the meadow tick, Dermacentor reticulatus, in southern Scandinavia, 2016

2019

Abstract The taiga tick, Ixodes persulcatus, has previously been limited to eastern Europe and northern Asia, but recently its range has expanded to Finland and northern Sweden. The species is of medical importance, as it, along with a string of other pathogens, may carry the Siberian and Far Eastern subtypes of tick-borne encephalitis virus. These subtypes appear to cause more severe disease, with higher fatality rates than the central European subtype. Until recently, the meadow tick, Dermacentor reticulatus, has been absent from Scandinavia, but has now been detected in Denmark, Norway and Sweden. Dermacentor reticulatus carries, along with other pathogens, Babesia canis and Rickettsia r…

0301 basic medicineNymphmeadow tickDermacentor reticulatus030231 tropical medicineZoologyIxodes persulcatusIxodes persulcatusTickScandinavian and Nordic CountriesSiberian and Far Eastern tick-borne encephalitisTaiga ticklcsh:Infectious and parasitic diseases03 medical and health sciences0302 clinical medicineDogsDermacentor reticulatusBabesiosisparasitic diseasesmedicineAnimalslcsh:RC109-216NymphLetter to the Editorrange expansionDermacentorSwedenTick-borne diseasebiologyIxodesNorwayTick-borne encephalitisArthropod VectorsBabesiosismedicine.diseasebiology.organism_classificationGrasslandTick Infestations030104 developmental biologyInfectious DiseasesTick-Borne DiseasesEpidemiological MonitoringBabesia canissouthern ScandinaviaParasitologyAnimal DistributionEncephalitis Tick-BorneParasites & Vectors
researchProduct

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and…

2019

Abstract Background The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). We analysed whether treatment intensification by the addition of docetaxel to PFC improved efficacy in R/M SCCHN. Methods A total of 180 patients with R/M SCCHN (1:1) were assigned to receive either cisplatin (40 mg/m2), docetaxel (40 mg/m2) and 5-FU (2000 mg/m2) at days 1 and 8 and cetuximab (400/250 mg/m2) at days 1, 8 and 15 (DPFC) or standard cisplatin (100 mg/m2) at day 1, 5-FU (1000 mg/m2) at days 1–4 and cetuximab (400/250 mg/m2) at days 1, 8 and 15 (PFC). Chemotherapy was…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinCetuximabDocetaxelDisease-Free SurvivalDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAgedCisplatinChemotherapyCetuximabbusiness.industrySquamous Cell Carcinoma of Head and NeckHead and neck cancerHazard ratioMiddle AgedInterim analysismedicine.disease030104 developmental biologyOncologyDocetaxelFluorouracil030220 oncology & carcinogenesisFemaleFluorouracilCisplatinbusinessmedicine.drug
researchProduct

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

2020

Simple Summary Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancer (RCC), with no data on its prevalence worldwide. No genotype-phenotype associations have been described. The aim of our study was to describe the genotypic and phenotypic features of the largest series of patients with HLRCC from Spain reported to date. Of 27 FH germline pathogenic variants, 12 were not previously reported in databases. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function varia…

0301 basic medicineOncologyCancer ResearchCancer cellsmedicine.disease_causeurologic and male genital diseases:Male Urogenital Diseases::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Male Urogenital Diseases::Carcinoma Renal Cell [DISEASES]<i>FH</i> gene0302 clinical medicineMalalties hereditàriesMissense mutationFH geneFH gene hereditary leiomyomatosis leiomyomas missense pathogenic variants renal cell cancerRenal cell cancerMutationKidney diseasesHereditary leiomyomatosis:Otros calificadores::Otros calificadores::/genética [Otros calificadores]:enfermedades urogenitales masculinas::neoplasias urogenitales::neoplasias urológicas::neoplasias renales::enfermedades urogenitales masculinas::carcinoma de células renales [ENFERMEDADES]leiomyomasmissense pathogenic variants renal cell cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRare diseases:Geographic Locations::Europe::Spain [GEOGRAPHICALS]Oncology030220 oncology & carcinogenesisCohortCèl·lules cancerosesMalalties raresRenal Cell CancersGenetic disordersmedicine.medical_specialtyMissense pathogenic variantsBiología Celularlcsh:RC254-282Article03 medical and health sciencesLeiomyomasInternal medicine:Other subheadings::Other subheadings::/genetics [Other subheadings]medicineRonyons - Malalties - Espanya:localizaciones geográficas::Europa (continente)::España [DENOMINACIONES GEOGRÁFICAS]business.industry:neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::leiomioma::leiomiomatosis [ENFERMEDADES]Retrospective cohort studymedicine.diseaseGenética030104 developmental biologyFumaraseClinical diagnosisHereditary leiomyomatosis and renal cell cancer syndromeMalalties del ronyó:Neoplasms::Neoplasms by Histologic Type::Neoplasms Connective and Soft Tissue::Neoplasms Muscle Tissue::Leiomyoma::Leiomyomatosis [DISEASES]hereditary leiomyomatosisbusiness
researchProduct

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

2018

Current treatment options for advanced and recurrent head and neck squamous cell carcinoma (HNSCC) enclose radiation and chemo-radiation approaches with or without surgery. While platinum-based chemotherapy regimens currently represent the gold standard in terms of efficacy and are given in the vast majority of cases, new chemotherapy regimens, namely immunotherapy are emerging. However, the response rates and therapy resistance mechanisms for either chemo regimen are hard to predict and remain insufficiently understood. Broad variations of chemo and radiation resistance mechanisms are known to date. This study describes the development of a standardized, high-throughput in vitro assay to a…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGeneral Chemical Engineeringmedicine.medical_treatmentCell Culture TechniquesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences3D cell culture0302 clinical medicineInternal medicinemedicineCarcinomaHumansPrecision MedicineChemotherapyGeneral Immunology and MicrobiologySquamous Cell Carcinoma of Head and Neckbusiness.industryGeneral NeuroscienceHead and neck cancerImmunotherapymedicine.diseaseHead and neck squamous-cell carcinoma3. Good healthRegimen030104 developmental biologyHead and Neck Neoplasms030220 oncology & carcinogenesisCarcinoma Squamous CellPersonalized medicinebusinessJournal of Visualized Experiments
researchProduct

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer.

2018

Background: Locally advanced head and neck squamous cell carcinoma (LAHNSCC) is a heterogeneous disease in which better predictive and prognostic factors are needed. Apart from TNM stage, both systemic inflammation and poor nutritional status have a negative impact on survival. Methods: We retrospectively analysed two independent cohorts of a total of 145 patients with LAHNSCC treated with induction chemotherapy followed by concurrent chemoradiotherapy at two different academic institutions. Full clinical data, including the Prognostic Nutritional Index (PNI), neutrophil to lymphocyte ratio and derived neutrophil to lymphocyte ratio, were analysed in a training cohort of 50 patients. Receiv…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisDerived neutrophil-to-lymphocyte ratio; Head and neck squamous cell carcinoma; Inflammation-based prognostic scores; Neutrophil-to-lymphocyte ratio; Overall survival; Prognostic factors; Prognostic nutritional indexoverall survivalhead and neck squamous cell carcinomaderived neutrophil-to-lymphocyte ratio03 medical and health sciences0302 clinical medicineneutrophil-to-lymphocyte ratioInternal medicinemedicine1506Stage (cooking)Neutrophil to lymphocyte ratioOriginal ResearchUnivariate analysisbusiness.industryHead and neck cancerInduction chemotherapyprognostic factorsprognostic nutritional indexmedicine.diseaseHead and neck squamous-cell carcinomaClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisinflammation-based prognostic scoresbusinessESMO open
researchProduct

Spheroid-based 3D Cell Cultures Enable Personalized Therapy Testing and Drug Discovery in Head and Neck Cancer.

2017

Background/Aim: Chemo-radiation currently serves as first-line therapy of advanced and recurrent head and neck cancer, while new chemotherapy regimens are emerging. However, response rates to any treatment are difficult to predict and underlie broad variation. This study shows the development of a standardized, high-throughput in vitro assay to assess patients' individual response to therapy regimens as a future tool for personalized tumor therapy. Materials and Methods: Viability and proliferation analyses after chemo +/- radiation treatment of single spheroids (low adhesion plates/Hanging Drop (HD)) were generated from head and neck squamous cell carcinoma (HNSCC) cell lines and primary h…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPathologyNecrosismedicine.medical_treatmentCell Culture TechniquesAntineoplastic Agents03 medical and health sciences3D cell culture0302 clinical medicineInternal medicineCell Line TumorSpheroids CellularDrug DiscoverymedicineTumor Cells CulturedHumansPrecision MedicineChemotherapybusiness.industryHead and neck cancerSpheroidGeneral MedicineChemoradiotherapymedicine.diseaseHead and neck squamous-cell carcinoma3. Good health030104 developmental biologyOncologyCell cultureHead and Neck Neoplasms030220 oncology & carcinogenesisPersonalized medicinemedicine.symptomDrug Screening Assays AntitumorbusinessAnticancer research
researchProduct

Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

2020

MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alterations in cancer patients. We analyzed MET amplification in circulating free DNA (cfDNA) from 174 patients with cancer and 49 healthy controls and demonstrated the accuracy of the analysis to detect its alteration in patients. Importantly, a significant correlation between cfDNA concentration and MET copy number (CN) in cancer patients (r = 0.57, p &lt

0301 basic medicineOncologyMale<i>MET</i> copy numbermedicine.medical_treatmentproteínas protooncogénicas c-metdosificación génicahumanosresistencia a medicamentosDrug ResistanceGene Dosagecirculating free DNA (cfDNA)<i>MET</i> amplificationTargeted therapyTargeted therapy0302 clinical medicineCirculating tumor cellestudios prospectivosNeoplasmsantineoplásicosProspective Studieslcsh:QH301-705.5Circulating tumor cells (CTCs)neoplasiasGeneral MedicineProto-Oncogene Proteins c-mettargeted therapyNeoplastic Cells CirculatingErbB ReceptorsCell-free fetal DNA030220 oncology & carcinogenesisinhibidores de proteína cinasasBiomarker (medicine)FemaleMET protein expressionCell-Free Nucleic AcidsMET amplificationmedicine.medical_specialtycirculating tumor cells (CTCs)estudios de casos y controlesMet amplificationCirculating free DNA (cfDNA)Antineoplastic AgentsArticle03 medical and health sciencesInternal medicinemedicineBiomarkers TumorHumansLiquid biopsyProtein Kinase InhibitorsRetrospective Studiesbusiness.industryHead and neck cancerestudios retrospectivosLiquid BiopsyCancermedicine.disease030104 developmental biologylcsh:Biology (General)Drug Resistance NeoplasmCase-Control StudiesMET copy numberbusinessCells
researchProduct

Ectopic myoglobin expression is associated with a favourable outcome in head and neck squamous cell carcinoma patients

2016

BACKGROUND/AIM: Ectopic myoglobin (MB) expression, mediated by alternative and hypoxia-inducible transcription, has recently been demonstrated in several epithelial tumours. This study aimed to examine the expression of MB in hormone-independent head and neck squamous cell carcinomas (HNSCCs). PATIENTS AND METHODS: Using imunohistochemistry, ectopic MB expression was analyzed on tissue microarrays (TMAs) of 524 patients with localized and locally advanced primary and recurrent HNSCC who had undergone surgical treatment with curative intent. Associations of MB expression with survival and clinicopathological parameters were analyzed. RESULTS: MB expression was found in 45.8% of HNSCC patient…

0301 basic medicineOncologyMaleCancer ResearchPathologyCellMedizinchemistry.chemical_compound0302 clinical medicineMedicine1306 Cancer ResearchHead and neckSurgical treatmentChildTissue microarrayMyoglobinHazard ratioGeneral MedicineMiddle Aged10081 Institute of Veterinary Physiologymedicine.anatomical_structureTreatment OutcomeOncologyMyoglobinHead and Neck Neoplasms030220 oncology & carcinogenesisChild PreschoolCarcinoma Squamous CellFemale2730 OncologyAdultmedicine.medical_specialtyHPVAdolescenthead and neck squamous cell carcinoma03 medical and health sciencesYoung AdultInternal medicineHumansbusiness.industryInfant NewbornInfantmedicine.diseaseHead and neck squamous-cell carcinomaConfidence interval030104 developmental biologychemistry570 Life sciences; biologyprognosisbusiness
researchProduct

Treatment patterns in elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results from an EORTC led survey

2018

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryLocally advancedHematologymedicine.diseaseHead and neck squamous-cell carcinoma03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicinebusiness
researchProduct

Optimization of Lead Placement in the Right Ventricle During Cardiac Resynchronization Therapy. A Simulation Study

2019

[EN] Patients suffering from heart failure and left bundle branch block show electrical ventricular dyssynchrony causing an abnormal blood pumping. Cardiac resynchronization therapy (CRT) is recommended for these patients. Patients with positive therapy response normally present QRS shortening and an increased left ventricle (LV) ejection fraction. However, around one third do not respond favorably. Therefore, optimal location of pacing leads, timing delays between leads and/or choosing related biomarkers is crucial to achieve the best possible degree of ventricular synchrony during CRT application. In this study, computational modeling is used to predict the optimal location and delay of p…

0301 basic medicineOptimizationcomputational modelingmedicine.medical_specialtyQRS durationPhysiologymedicine.medical_treatmentCardiac resynchronization therapycardiac resynchronization therapyheart failureHeart failureLBBB030204 cardiovascular system & hematologylcsh:PhysiologyTECNOLOGIA ELECTRONICA03 medical and health sciencesQRS complex0302 clinical medicinePhysiology (medical)Internal medicinemedicinecardiovascular diseasesOriginal ResearchCardiac resynchronization therapylcsh:QP1-981business.industryComputational modelingmedicine.disease030104 developmental biologymedicine.anatomical_structureVentricleHeart failureCardiologycardiovascular systemLead PlacementbusinessoptimizationFrontiers in Physiology
researchProduct